...
首页> 外文期刊>Journal of Clinical Medicine >Role of Type2 Inflammatory Biomarkers in Chronic Obstructive Pulmonary Disease
【24h】

Role of Type2 Inflammatory Biomarkers in Chronic Obstructive Pulmonary Disease

机译:Type2炎症生物标志物在慢性阻塞性肺病中的作用

获取原文
           

摘要

Airway inflammation in chronic obstructive pulmonary disease (COPD) is typically thought to be driven by Type1 immune responses, while Type2 inflammation appears to be present in definite proportions in the stable state and during exacerbations. In fact, some COPD patients showed gene expression of Type2 inflammation in the airway, and this subset was associated with the inhaled corticosteroid (ICS) response. Interestingly enough, the relationship between COPD and diseases associated with Type2 inflammation from the perspective of impaired lung development is increasingly highlighted by recent epidemiologic studies on the origin of COPD. Therefore, many researchers have shown an interest in the prevalence and the role of existent Type2 biomarkers such as sputum and blood eosinophils, exhaled nitric oxide fraction, and atopy, not only in asthma but also in COPD. Although the evidence about Type2 biomarkers in COPD is inconsistent and less robust, Type2 biomarkers have shown some potential when analyzing various clinical outcomes or therapeutic response to ICS. In this article, we review the existent and emerging Type2 biomarkers with clinically higher applicability in the management of COPD.
机译:慢性阻塞性肺病(COPD)的气道炎症通常被认为是由Type1免疫应答驱动的,而Type2炎症似乎以稳定状态和加剧期间的明确比例存在。事实上,一些COPD患者在气道中显示出Type2炎症的基因表达,并且该子集与吸入的皮质类固醇(ICS)反应有关。有趣的是,最近对COPD起源的流行病学研究越来越强调了与肺部肺部发作的角度相关的COPD与疾病相关的关系。因此,许多研究人员对存在的痰和血液粒细胞,呼出的一氧化氮馏分和特性,而且不仅在哮喘而且在COPD中,也表现出对存在的患病率和存在的作用。虽然COPD中关于Type2生物标志物的证据是不一致的,并且在分析各种临床结果或对IC的治疗反应时,Type2的生物标志物已经显示出一些潜力。在本文中,我们在COPD管理中审查了存在的和新兴的生物标志物,在临床上具有临床上的适用性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号